News
07-19-2011, 05:10 AM
Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown. ABT-737 is one of a new class of anti-cancer agents called BH3 mimetics that target and neutralise the so-called Bcl-2 proteins in cancer cells...
More... (http://www.medicalnewstoday.com/releases/231330.php)
More... (http://www.medicalnewstoday.com/releases/231330.php)